The global Biotechnology market size reached USD 761.5 Billion in 2024 and is expected to reach USD 1,315.9 Billion by 2033, growing at a CAGR of 6.27% during the forecast period 2025–2033. Major growth drivers include advancements in genetic engineering, increasing R&D in personalized medicine, and rising demand for sustainable agriculture. Biotechnology is pivotal to innovations in healthcare, agriculture, and environmental management. 

Study Assumption Years

• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033

Biotechnology Market Key Takeaways

• Current Market Size: USD 761.5 Billion in 2024
• CAGR: 6.27% (2025-2033)
• Forecast Period: 2025-2033
• Rapid advancements in genetic engineering including CRISPR-Cas9 technology are revolutionizing applications in medicine, agriculture, and industrial processes.
• Personalized medicine demand is accelerating the development of targeted therapies based on genomic analysis and biopharmaceuticals like monoclonal antibodies.
• Sustainable agriculture solutions are growing with GMOs and biopesticides improving yield, pest resistance, and reducing environmental impact.
• North America dominates the market due to its robust research ecosystem, strong R&D investments, and a supportive regulatory framework.
• Integration of AI and machine learning is accelerating drug discovery and development processes.

Sample Request Link: 

https://www.imarcgroup.com/biotechnology-market/requestsample

Market Growth Factors

The biotechnology market growth is primarily driven by rapid innovation in genetic engineering. The report highlights the revolutionary impact of CRISPR-Cas9 technology, enabling precise gene editing within organisms, which creates significant applications in healthcare, agriculture, and industrial manufacturing. This innovation facilitates the development of gene therapies for genetic disorders and cancers and enhances the biomanufacturing of compounds like insulin and enzymes, fueling market expansion with increased research output and product innovation.

The rising demand for personalized medicine is another key factor. With advancements in genomic sequencing technology, individual genetic codes can be analyzed to develop targeted therapies that increase treatment efficacy and reduce side effects. Biopharmaceuticals, such as monoclonal antibodies and gene therapies, align closely with personalized medicine principles, revolutionizing healthcare by enabling early disease detection and prognosis based on genetic markers, thereby ushering a shift towards precision medicine approaches.

Sustainable agriculture also needs to propel the biotechnology market. Increasing global food demand, environmental concerns, and limited cultivable land necessitate sustainable solutions. Genetically modified crops engineered for better yield, pest resistance, and nutrition, as well as biopesticides with lower ecological impact, are examples of biotechnology applications transforming farming practices. Such technologies optimize plant traits, improve crop resilience to climate change, and enhance nutrient utilization, contributing to food security and sustainable resource management.

Market Segmentation

Breakup by Product Type:

• Instruments: Foundation for advanced research and diagnostics enabling precise analysis and experimentation.
• Reagents: Essential for fueling experimental processes, facilitating accurate results and scientific breakthroughs.
• Software and Services: Software provides data analysis, visualization, and integration; services include consulting, training, and technical support to maximize tool utilization and collaboration.

Breakup by Technology:

• Nanobiotechnology: Integration of nanoscale materials with biological systems transforming drug delivery and diagnostics.
• Tissue Engineering and Regeneration: Innovative methods to create functional tissues addressing organ shortages and medical demands.
• DNA Sequencing: Enables comprehensive genomic analysis guiding personalized medicine and understanding diseases.
• Cell-Based Assays: Offers insights into cellular behavior supporting drug development and toxicity testing.
• Fermentation: Key bioprocess producing biofuels, pharmaceuticals, and enzymes.
• PCR Technology: DNA amplification critical for diagnostics and genetic research.
• Chromatography: Precision separation of biomolecules essential in drug purification and analytics.
• Others: Additional biotechnological methods and tools not classified elsewhere.

Breakup by Application:

• Healthcare: Dominates the market, driving innovations in diagnostics, personalized medicine, advanced DNA sequencing, and biopharmaceuticals.
• Food and Agriculture: Application of GMOs, biopesticides, and sustainable farming methods.
• Natural Resources and Environment: Biotechnological solutions for environmental management and bioremediation.
• Industrial Processing: Use of biotechnology in industrial manufacturing and processing.
• Bioinformatics: Integration of IT with biotechnology to optimize R&D.
• Others: Additional applications not specifically listed.

Regional Insights

North America holds the largest market share, supported by a robust ecosystem of research, innovation, and industry collaboration. The region's strong R&D investments and well-established regulatory frameworks contribute to biotechnological breakthroughs. A history of achievements in genomics, pharmaceuticals, and medical devices underscores North America's influential role in shaping the global biotechnology landscape. Initiatives like the 'Biotech Across America' roadshow further emphasize its leadership, workforce development, and biopharma manufacturing growth.

Recent Developments & News

In May 2025, Biogen and City Therapeutics partnered to develop RNA interference (RNAi) therapies for central nervous system diseases, with Biogen leading clinical development and commercialization. In the same month, Biocon Biologics launched a biosimilar to Stelara in Japan, expanding its biologics footprint. In April 2025, Novartis announced a USD 23 Billion US investment plan including seven new facilities and 5,000 new jobs. Amgen invested USD 900 Million to expand its Ohio biologics manufacturing site, raising total investments over USD 1.4 Billion. In March 2025, Roche opened an innovation center in Boston focusing on cardiovascular and metabolic R&D and AI-driven drug discovery.

Key Players

• Amgen Inc.
• Biocon Limited
• Biogen Inc.
• F. Hoffmann-La Roche AG
• Genmab A/S
• Lonza Group AG
• Novartis AG
• Novo Nordisk A/S
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Seagen Inc.
• Syngenta AG
• Vertex Pharmaceuticals Incorporated

Customization Note

https://www.imarcgroup.com/request?type=report&id=5785&flag=C

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302